Flagship Pioneering merges three of its companies for AI drug discovery

Flagship Pioneering merges Etiome, Cellarity and Empress Therapeutics into Etcelera

Biotechnology startup creator Flagship Pioneering is combining three of its portfolio companies—Etiome, Cellarity, and Empress Therapeutics—into a new venture called Etcelera. The merged company will use artificial intelligence and drug discovery tools to predict which experimental medicines might succeed in clinical trials.